ACKR4

Summary

ACKR4 (atypical chemokine receptor 4, HGNC:1611) is a protein-coding gene on chromosome 3q22.1, encoding Atypical chemokine receptor 4 (Q9NPB9). Atypical chemokine receptor that controls chemokine levels and localization via high-affinity chemokine binding that is uncoupled from classic ligand-driven signal transduction cascades, resulting instead in chemokine sequestration, degradation, or transcytosis.

The protein encoded by this gene is a member of the G protein-coupled receptor family, and is a receptor for C-C type chemokines. This receptor has been shown to bind dendritic cell- and T cell-activated chemokines including CCL19/ELC, CCL21/SLC, and CCL25/TECK. A pseudogene of this gene is found on chromosome 6. Alternatively spliced transcript variants encoding the same protein have been described.

Source: NCBI Gene 51554 — RefSeq curated summary.

At a glance

• GWAS associations: 5
• Clinical variants (ClinVar): 1 total
• MANE Select transcript: NM_016557

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:1611
Approved symbol	ACKR4
Name	atypical chemokine receptor 4
Location	3q22.1
Locus type	gene with protein product
Status	Approved
Aliases	CCR11, CCBP2, VSHK1, CCX-CKR, PPR1
Ensembl gene	ENSG00000129048
Ensembl biotype	protein_coding
OMIM	606065
Entrez	51554

Gene structure

Transcript identifiers

Ensembl transcripts: 4 — 3 protein_coding, 1 nonsense_mediated_decay

ENST00000249887, ENST00000509820, ENST00000878670, ENST00000964709

RefSeq mRNA: 2 — MANE Select: NM_016557 NM_016557, NM_178445

CCDS: CCDS3075

Canonical transcript exons

ENST00000249887 — 2 exons

Exon	Start	End
ENSE00000885857	132600389	132602644
ENSE00001231496	132597270	132597323

Expression profiles

Bgee: expression breadth ubiquitous, 132 present calls, max score 86.15.

FANTOM5 (CAGE): breadth broad, TPM avg 4.7280 / max 270.4053, expressed in 392 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
38634	4.5240	388
38633	0.2040	91

Top tissues by expression

137 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
duodenum	UBERON:0002114	86.15	gold quality
ascending aorta	UBERON:0001496	79.95	gold quality
thoracic aorta	UBERON:0001515	79.92	gold quality
gall bladder	UBERON:0002110	78.60	gold quality
descending thoracic aorta	UBERON:0002345	76.92	gold quality
subcutaneous adipose tissue	UBERON:0002190	76.73	gold quality
right coronary artery	UBERON:0001625	75.96	gold quality
skin of leg	UBERON:0001511	75.61	gold quality
zone of skin	UBERON:0000014	75.39	gold quality
calcaneal tendon	UBERON:0003701	75.09	gold quality
skin of abdomen	UBERON:0001416	74.88	gold quality
pituitary gland	UBERON:0000007	74.58	gold quality
right atrium auricular region	UBERON:0006631	73.78	gold quality
adipose tissue	UBERON:0001013	71.97	gold quality
heart	UBERON:0000948	71.79	gold quality
small intestine	UBERON:0002108	71.47	gold quality
heart left ventricle	UBERON:0002084	71.27	gold quality
lung	UBERON:0002048	71.15	gold quality
smooth muscle tissue	UBERON:0001135	71.06	gold quality
adenohypophysis	UBERON:0002196	71.06	gold quality
upper lobe of left lung	UBERON:0008952	70.99	gold quality
tonsil	UBERON:0002372	70.87	gold quality
small intestine Peyer’s patch	UBERON:0003454	70.52	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	70.48	gold quality
apex of heart	UBERON:0002098	70.26	gold quality
body of stomach	UBERON:0001161	70.25	gold quality
popliteal artery	UBERON:0002250	70.15	gold quality
thoracic mammary gland	UBERON:0005200	70.14	gold quality
tibial artery	UBERON:0007610	70.14	gold quality
right uterine tube	UBERON:0001302	69.94	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	3.37
E-MTAB-10290	no	294.95

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

69 targeting ACKR4, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-513A-5P	100.00	69.77	2465
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-568	99.98	69.86	2084
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-493-5P	99.96	72.47	2382
HSA-MIR-1-3P	99.93	72.35	1914
HSA-MIR-206	99.93	72.50	1893
HSA-MIR-3119	99.92	71.34	2390
HSA-MIR-1297	99.91	73.41	3162
HSA-MIR-10527-5P	99.91	72.28	3754
HSA-MIR-613	99.91	71.50	1710
HSA-MIR-374A-5P	99.90	71.34	2923
HSA-MIR-374B-5P	99.90	69.98	2734
HSA-MIR-137-3P	99.87	74.74	2401
HSA-MIR-5582-3P	99.86	72.48	4221
HSA-MIR-629-3P	99.85	67.99	1875
HSA-MIR-765	99.84	68.24	2442
HSA-MIR-944	99.82	70.85	3042
HSA-MIR-4307	99.82	70.45	3374
HSA-MIR-489-3P	99.80	66.46	839

Literature-anchored findings (GeneRIF, showing 18)

• Characterization of mouse CCX-CKR, a receptor for the lymphocyte-attracting chemokines TECK/mCCL25, SLC/mCCL21 and MIP-3beta/mCCL19: comparison to human CCX-CKR. (PMID:11981810)
• Scavenges extracellular chemokines in vivo to modify responses through CCR7. (PMID:16791897)
• Down regulation of CCX-CKR is associated with breast cancer. (PMID:19383822)
• Data suggest that co-expression of CCX-CKR and CXCR3 (chemokine receptor type 3) in T-lymphocytes results in protein multimerization and prevents CXCR3-mediated chemotaxis; this represents a novel mechanism of regulation of immune cell migration. (PMID:23121557)
• Results suggest that chemokine binding to CCX-CKR recruits Gi proteins and beta-arrestin (beta-arr) with high affinity. (PMID:23341447)
• co-expression of DARC, D6, and CCX-CKR significantly associated with higher survival in gastric cancer (PMID:23462454)
• Effect of genetic variants in two chemokine decoy receptor genes, DARC and CCBP2, on metastatic potential of breast cancer. (PMID:24260134)
• we found that CCX-CKR expression in vitro could modulate cellular migration and invasion abilities, potentially via the regulation of other chemotactic factors/receptors. (PMID:24338720)
• Results of this study show that HEK 293 cells express an endogenous CCRL1 gene only at mRNA level. These data therefore represent the important implications for the use of HEK 293 cells as a host cell system for the study of CCX-CKR. (PMID:26699909)
• CCL19-mRFP and CCL21-mRFP are versatile and powerful tools to study CCR7 and ACKR4 functions. (PMID:30518137)
• ACKR4 Recruits GRK3 Prior to beta-Arrestins but Can Scavenge Chemokines in the Absence of beta-Arrestins. (PMID:32391018)
• Systematic reassessment of chemokine-receptor pairings confirms CCL20 but not CXCL13 and extends the spectrum of ACKR4 agonists to CCL22. (PMID:32480426)
• CCL20 is a novel ligand for the scavenging atypical chemokine receptor 4. (PMID:32533638)
• Biphasic Expression of Atypical Chemokine Receptor (ACKR) 2 and ACKR4 in Colorectal Neoplasms in Association with Histopathological Findings. (PMID:33374792)
• The relation between ACKR4 and CCR7 genes expression and breast cancer metastasis. (PMID:34102193)
• Mechanosensitive ACKR4 scavenges CCR7 chemokines to facilitate T cell de-adhesion and passive transport by flow in inflamed afferent lymphatics. (PMID:35108538)
• Identification of ACKR4 as an immune checkpoint in pulmonary arterial hypertension. (PMID:37449198)
• Atypical chemokine receptor 4 (ACKR4/CCX-CKR): A comprehensive exploration across physiological and pathological landscapes in contemporary research. (PMID:38597217)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	ackr4b	ENSDARG00000040133
danio_rerio	ackr4a	ENSDARG00000078729
mus_musculus	Ackr4	ENSMUSG00000079355
rattus_norvegicus	Ackr4	ENSRNOG00000011478

Paralogs (23): CCR6 (ENSG00000112486), CCRL2 (ENSG00000121797), CCR2 (ENSG00000121807), CXCR4 (ENSG00000121966), CCR7 (ENSG00000126353), ACKR3 (ENSG00000144476), ACKR2 (ENSG00000144648), RGR (ENSG00000148604), CXCR5 (ENSG00000160683), CCR5 (ENSG00000160791), CXCR1 (ENSG00000163464), CCR1 (ENSG00000163823), CX3CR1 (ENSG00000168329), CXCR6 (ENSG00000172215), XCR1 (ENSG00000173578), CCR9 (ENSG00000173585), CCR8 (ENSG00000179934), CXCR2 (ENSG00000180871), GALR2 (ENSG00000182687), CCR3 (ENSG00000183625), CCR4 (ENSG00000183813), CCR10 (ENSG00000184451), CXCR3 (ENSG00000186810)

Protein

Protein identifiers

Atypical chemokine receptor 4 — Q9NPB9 (reviewed: Q9NPB9)

Alternative names: C-C chemokine receptor type 11, CC chemokine receptor-like 1, CCX CKR

All UniProt accessions (2): Q9NPB9, H0Y9Z2

UniProt curated annotations — full annotation on UniProt →

Function. Atypical chemokine receptor that controls chemokine levels and localization via high-affinity chemokine binding that is uncoupled from classic ligand-driven signal transduction cascades, resulting instead in chemokine sequestration, degradation, or transcytosis. Also known as interceptor (internalizing receptor) or chemokine-scavenging receptor or chemokine decoy receptor. Acts as a receptor for chemokines CCL2, CCL8, CCL13, CCL19, CCL21 and CCL25. Chemokine-binding does not activate G-protein-mediated signal transduction but instead induces beta-arrestin recruitment, leading to ligand internalization. Plays an important role in controlling the migration of immune and cancer cells that express chemokine receptors CCR7 and CCR9, by reducing the availability of CCL19, CCL21, and CCL25 through internalization. Negatively regulates CXCR3-induced chemotaxis. Regulates T-cell development in the thymus.

Subunit / interactions. Forms heteromers with CXCR3. Interacts with ARRB1 and ARRB2.

Subcellular location. Early endosome. Recycling endosome. Cell membrane.

Tissue specificity. Predominantly expressed in heart. Lower expression in lung, pancreas, spleen, colon, skeletal muscle and small intestine.

Post-translational modifications. The Ser/Thr residues in the C-terminal cytoplasmic tail may be phosphorylated.

Similarity. Belongs to the G-protein coupled receptor 1 family. Atypical chemokine receptor subfamily.

RefSeq proteins (2): NP_057641, NP_848540 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000276	GPCR_Rhodpsn	Family
IPR000355	Chemokine_rcpt	Family
IPR005383	ACKR4	Family
IPR017452	GPCR_Rhodpsn_7TM	Domain
IPR050119	CCR1-9-like	Family

Pfam: PF00001

UniProt features (19 total): topological domain 8, transmembrane region 7, glycosylation site 2, chain 1, disulfide bond 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9NPB9-F1	81.55	0.36

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (1): 112–184

Glycosylation sites (2): 6, 19

Function

Pathways and Gene Ontology

Reactome pathways

6 pathways

ID	Pathway
R-HSA-380108	Chemokine receptors bind chemokines
R-HSA-162582	Signal Transduction
R-HSA-372790	Signaling by GPCR
R-HSA-373076	Class A/1 (Rhodopsin-like receptors)
R-HSA-375276	Peptide ligand-binding receptors
R-HSA-500792	GPCR ligand binding

MSigDB gene sets: 115 (showing top): GOBP_CELL_CHEMOTAXIS, GOBP_RESPONSE_TO_PEPTIDE, JAEGER_METASTASIS_DN, GOCC_CELL_SURFACE, GOBP_VESICLE_MEDIATED_TRANSPORT, GOBP_TAXIS, REACTOME_PEPTIDE_LIGAND_BINDING_RECEPTORS, GARY_CD5_TARGETS_DN, WANG_CISPLATIN_RESPONSE_AND_XPC_DN, HU_GENOTOXIN_ACTION_DIRECT_VS_INDIRECT_4HR, VECCHI_GASTRIC_CANCER_EARLY_DN, chr3q22, TGGAAA_NFAT_Q4_01, GOCC_SIDE_OF_MEMBRANE, GOCC_RECYCLING_ENDOSOME

GO Biological Process (9): chemotaxis (GO:0006935), immune response (GO:0006955), G protein-coupled receptor signaling pathway (GO:0007186), positive regulation of cytosolic calcium ion concentration (GO:0007204), calcium-mediated signaling (GO:0019722), cell chemotaxis (GO:0060326), signal transduction (GO:0007165), vesicle-mediated transport (GO:0016192), chemokine-mediated signaling pathway (GO:0070098)

GO Molecular Function (7): chemokine receptor activity (GO:0004950), scavenger receptor activity (GO:0005044), C-C chemokine receptor activity (GO:0016493), C-C chemokine binding (GO:0019957), G protein-coupled receptor activity (GO:0004930), protein binding (GO:0005515), chemokine binding (GO:0019956)

GO Cellular Component (6): early endosome (GO:0005769), plasma membrane (GO:0005886), external side of plasma membrane (GO:0009897), recycling endosome (GO:0055037), endosome (GO:0005768), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-5 pathways:

Category	Pathways
Peptide ligand-binding receptors	1
Signal Transduction	1
GPCR ligand binding	1
Class A/1 (Rhodopsin-like receptors)	1
Signaling by GPCR	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular process	2
G protein-coupled receptor signaling pathway	2
chemokine binding	2
endosome	2
response to chemical	1
taxis	1
immune system process	1
response to stimulus	1
G protein-coupled receptor activity	1
signal transduction	1
regulation of biological quality	1
intracellular signaling cassette	1
chemotaxis	1
cell migration	1
cellular response to chemical stimulus	1
cell communication	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
transport	1
cytokine-mediated signaling pathway	1
cellular response to chemokine	1
G protein-coupled chemoattractant receptor activity	1
cytokine receptor activity	1
chemokine-mediated signaling pathway	1
cargo receptor activity	1
chemokine receptor activity	1
C-C chemokine binding	1
transmembrane signaling receptor activity	1
binding	1
cytokine binding	1
membrane	1
cell periphery	1
plasma membrane	1
cell surface	1
side of membrane	1
endomembrane system	1
cytoplasmic vesicle	1
cellular anatomical structure	1

Protein interactions and networks

STRING

1006 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ACKR4	CCL27	Q9Y4X3	998
ACKR4	CCL21	O00585	997
ACKR4	CCL25	O15444	995
ACKR4	CCL19	Q99731	992
ACKR4	CXCL13	O43927	990
ACKR4	CCL17	Q92583	978
ACKR4	CCL22	O00626	940
ACKR4	CCL5	P13501	938
ACKR4	CCL20	P78556	928
ACKR4	CXCL12	P48061	858
ACKR4	CCL8	P78388	816
ACKR4	MADCAM1	Q13477	777
ACKR4	ACKR1	Q16570	742
ACKR4	CCL2	P13500	739
ACKR4	NECTIN3	Q9NQS3	684

IntAct

5 interactions, top by confidence:

A	B	Type	Score
ACKR4	SURF6	psi-mi:“MI:0915”(physical association)	0.400
ACKR4	ATP12A	psi-mi:“MI:0915”(physical association)	0.400
ACKR4	CDK2	psi-mi:“MI:0915”(physical association)	0.370
ACKR4	CXCR3	psi-mi:“MI:2364”(proximity)	0.270

BioGRID (8): CXCL13 (Reconstituted Complex), CCL21 (Reconstituted Complex), CCL25 (Reconstituted Complex), CCL19 (Reconstituted Complex), SURF6 (Affinity Capture-MS), ATP12A (Affinity Capture-MS), ACKR4 (Positive Genetic), CDK2 (Two-hybrid)

ESM2 similar proteins: A1A5S3, A5PLE7, B0UXR0, B5X337, F5HDK1, F5HF62, F8VQN3, O00421, O18982, O97663, P09703, P32249, P35351, P35374, P46002, P49685, P50052, P51676, P56412, P69332, P69333, Q01035, Q0II78, Q0VDU3, Q14330, Q1RMI1, Q28929, Q3T0E9, Q3U507, Q4R613, Q6IYF9, Q75ZH0, Q83207, Q89609, Q8BZR0, Q8IYL9, Q8K1Z6, Q95N03, Q96P67, Q98146

Diamond homologs: O00574, O08556, O08565, O18793, O18983, O19024, O54689, O54814, O55193, O62743, O62747, O97571, O97878, O97879, O97880, O97881, O97883, O97962, O97975, P21109, P25025, P25930, P32246, P32248, P35343, P35344, P35350, P35407, P41597, P47774, P49682, P51677, P51678, P51679, P51680, P51681, P51683, P51684, P51686, P56439

SIGNOR signaling

3 interactions.

A	Effect	B	Mechanism
CCL19	“up-regulates activity”	ACKR4	binding
CCL21	“up-regulates activity”	ACKR4	binding
CCL25	“up-regulates activity”	ACKR4	binding

Disease & clinical

Clinical variants and AI predictions

ClinVar

1 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	1
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

721 predictions. Top by Δscore:

Variant	Effect	Δscore
3:132597916:T:G	donor_gain	1.0000
3:132603221:ACACT:A	donor_loss	1.0000
3:132603222:CACTC:C	donor_loss	1.0000
3:132603223:ACTCA:A	donor_loss	1.0000
3:132603224:CTCA:C	donor_loss	1.0000
3:132603225:TCACC:T	donor_loss	1.0000
3:132603226:CA:C	donor_loss	1.0000
3:132603227:A:AC	donor_gain	1.0000
3:132603228:C:CC	donor_gain	1.0000
3:132603228:C:CT	donor_loss	1.0000
3:132603228:CCA:C	donor_gain	1.0000
3:132603324:GGTT:G	acceptor_gain	1.0000
3:132603325:GTT:G	acceptor_gain	1.0000
3:132603326:TT:T	acceptor_gain	1.0000
3:132603326:TTC:T	acceptor_loss	1.0000
3:132603327:TCTA:T	acceptor_loss	1.0000
3:132603328:C:CC	acceptor_gain	1.0000
3:132603328:CT:C	acceptor_loss	1.0000
3:132603329:T:A	acceptor_loss	1.0000
3:132618677:T:TA	donor_gain	1.0000
3:132597916:T:TG	donor_gain	0.9900
3:132597920:G:GG	donor_gain	0.9900
3:132600384:TCTA:T	acceptor_loss	0.9900
3:132600385:CTAGA:C	acceptor_loss	0.9900
3:132600386:TAGA:T	acceptor_loss	0.9900
3:132600387:A:AG	acceptor_gain	0.9900
3:132600387:A:C	acceptor_loss	0.9900
3:132600388:G:GC	acceptor_loss	0.9900
3:132600388:G:GG	acceptor_gain	0.9900
3:132600388:GATT:G	acceptor_gain	0.9900

AlphaMissense

2317 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
3:132600797:A:C	S134R	0.996
3:132600799:C:A	S134R	0.996
3:132600799:C:G	S134R	0.996
3:132600712:G:C	W105C	0.995
3:132600712:G:T	W105C	0.995
3:132600488:T:A	C31S	0.994
3:132600489:G:C	C31S	0.994
3:132600657:A:C	D87A	0.994
3:132600710:T:A	W105R	0.993
3:132600710:T:C	W105R	0.993
3:132600731:T:A	C112S	0.992
3:132600732:G:C	C112S	0.992
3:132600488:T:C	C31R	0.990
3:132600560:G:A	G55R	0.990
3:132600560:G:C	G55R	0.990
3:132600657:A:T	D87V	0.990
3:132600902:A:C	S169R	0.990
3:132600904:C:A	S169R	0.990
3:132600904:C:G	S169R	0.990
3:132600947:T:A	C184S	0.990
3:132600948:G:C	C184S	0.990
3:132601142:T:C	F249L	0.990
3:132601144:C:A	F249L	0.990
3:132601144:C:G	F249L	0.990
3:132600731:T:C	C112R	0.989
3:132600881:T:A	W162R	0.989
3:132600881:T:C	W162R	0.989
3:132601161:C:G	P255R	0.989
3:132600561:G:A	G55E	0.988
3:132600658:T:A	D87E	0.988

dbSNP variants (sampled 300 via entrez): RS1000006957 (3:132598059 A>G), RS1000054354 (3:132597749 C>T), RS1000847872 (3:132599532 A>T), RS1001008231 (3:132596366 C>A), RS1001060487 (3:132596072 C>A), RS1001298017 (3:132602559 TA>T,TAA), RS1001392425 (3:132602876 C>G,T), RS1001676846 (3:132599583 G>C), RS1001729371 (3:132599273 C>T), RS1002305250 (3:132600254 A>G), RS1003852378 (3:132602702 C>T), RS1004011931 (3:132602673 A>C), RS1004354036 (3:132601480 T>C), RS1005067464 (3:132598925 T>C), RS1005424945 (3:132599196 A>C)

Disease associations

OMIM: gene MIM:606065 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

5 associations (top):

Study	Trait	p-value
GCST006622_17	Neonatal cytokine/chemokine levels (fetal genetic effect)	3.000000e-10
GCST010699_54	Brain morphology (min-P)	5.000000e-08
GCST010701_80	Cortical surface area (MOSTest)	5.000000e-09
GCST010702_60	Subcortical volume (MOSTest)	6.000000e-12
GCST010703_12	Brain morphology (MOSTest)	9.000000e-10

EFO canonical traits (4, from GWAS)

EFO ID	Trait name
EFO:0004747	protein measurement
EFO:0007959	fetal genotype effect measurement
EFO:0009416	CCL21 measurement
EFO:0004346	neuroimaging measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: gpcr — Chemokine receptors

Most potent curated ligand interactions (3 total), top 3:

Ligand	Action	Affinity	Parameter
CCL19	Agonist	8.4	pKi
CCL25	Agonist	7.6	pKi
CCL21	Agonist	6.9	pKi

CTD chemical–gene interactions

10 total (human), top 10 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Progesterone	decreases expression, increases expression	2
perfluorooctanoic acid	decreases expression	1
monomethylarsonous acid	increases expression	1
incobotulinumtoxinA	increases expression	1
Folic Acid	affects expression	1
Nickel	increases expression	1
Tetrachlorodibenzodioxin	increases expression	1
Tobacco Smoke Pollution	decreases expression	1
Valproic Acid	decreases methylation	1
Antirheumatic Agents	increases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.